Sarepta Therapeutics Inc (SRPT)

Muscular Dystrophy, Duchenne · registered primary completion 2026-10-31 · NCT03992430

Published 2026-09-02Market cap $2,203M6 sourced statements

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON) · PHASE3 · n=160 · active not recruiting

Share count and dilution

fact

105,627,021 shares outstanding against 133,471,021 if every outstanding option, warrant and convertible were exercised. In that case 20.9% of a gain in enterprise value would accrue to those holders rather than to current shareholders.

Source: antidilutive-securities disclosure, 10-Q filed 2026-08-05

Market

fact

No approved product carries Muscular Dystrophy, Duchenne on label.

Source: FDA label index

Trial registry

fact

Registered design for NCT03992430: randomized, quadruple-masked, 160 participants (actual). Primary outcome: Part 1: Incidence of Adverse Events (AEs). 2 further primary outcome(s) registered.

Source: ClinicalTrials.gov record

Regulatory

fact

Designations disclosed: RMAT, Breakthrough Therapy, Fast Track, Orphan Drug, Priority Review Voucher. These accelerate review and, for Orphan, confer exclusivity if approved; none is evidence of efficacy.

Source: 10-Q filed 2026-08-05

Pipeline

fact

11 distinct molecules in 10 active company-sponsored trials; delandistrogene moxeparvovec accounts for 3 of them at Phase 1/Phase 3.

Source: ClinicalTrials.gov, company as lead sponsor

Ownership and proceedings

fact

Directors and executive officers as a group hold 6.9%.

Source: DEF 14A filed 2026-04-24

This sheet is dated and will not be edited. When the registered primary completion passes, its outcome is recorded on the scoreboard and a new dated sheet is published if the filings change materially.